Advertisement

Topics

The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata

2014-07-23 21:12:22 | BioPortfolio

Summary

Alopecia areata is one of the most common cause of non-scarring alopecia. The pathogenesis is still unclear, however, it is believed to be an autoimmune disease. This disease is not a life-threatening condition but it has a significant psychological impact to patient's quality of life.

Many triggers have been proposed such as viral infection, stress and neurologic factors. There are many studies show the correlation between disease activities and neurotransmitters level. Substance P and calcitonin gene-related peptide play major role in early stage of disease. These substances cause imbalance of CD4/CD8 lymphocyte in pathologic site and loss of immune privilege of hair follicles.

The conventional treatment of alopecia areata with intralesional corticosteroid injection might treat the end of pathogenesis process.

There is no therapeutic intervention for the origin of disease. Fortunately, botulinum toxin A could be a novel treatment of alopecia areata. The botulinum toxin A demonstrates inhibition release of substance P in many publications.

To sum up, the treatment of alopecia areata with intralesional corticosteroid injection still be a standard treatment, nevertheless, patients have to receive this treatment every month until regrowth of scalp hair. Corticosteroid injection have several side effects, for example, skin atrophy, pigmentary change and hypothalamic-pituitary-adrenal axis suppression. Moreover, injection pain is also affect to psychological aspect .

This study purpose is to evaluate the efficacy of botulinum toxin A for alopecia areata and reduce corticosteroid side effects, as well as, others opportunity cost. There is no prospective, randomized-controlled trial of comparison study between botulinum toxin A injection and corticosteroid injection for alopecia areata, therefore, investigators conduct this study for the greatest benefit to alopecia areata patients and for the future research in disease etiology.

Description

Inclusion criteria

1. Patients must be above 18 years old

2. Newly diagnosed with multiple alopecia areata

3. Patient has lesions on the both side of the scalp.

4. Lesions's diameter varies between 2-6 cms

Exclusion criteria

1. Having active scalp inflammation

2. Allergic to botulinum toxin A or human albumin

3. Receiving any medication that interfere efficacy of botulinum toxin such as macrolides antimicrobial agents or neuromuscular medications

4. Diagnosed with neuromuscular diseases such as Myasthenia gravis

5. Pregnant, breast feeding, plan to pregnant patients

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Conditions

Alopecia Areata

Intervention

Botulinum toxin type A, Triamcinolone acetonide

Location

Department of Dermatology, Faculty of medicine Siriraj Hospital, Mahidol University
Bangkok
Thailand
10700

Status

Not yet recruiting

Source

Siriraj Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:12:22-0400

Clinical Trials [782 Associated Clinical Trials listed on BioPortfolio]

Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

Alopecia areata (AA) presents with circumscribed patches of non-scarring hair loss. It inflects a significant psychological and social burden. Many treatment options are used for the treat...

Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation

Alopecia areata is the most frequent cause of inflammation-induced hair loss with prevalence from 0.1 to 0.2%. It has no age nor sex predilection . Clinically, alopecia areata presents as...

The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis

The main purpose of this study is to determine the efficacy of intralesional botulinum toxin type A injection for recalcitrant alopecia totalis and alopecia universalis. Treatments of rec...

Alefacept in Patients With Severe Scalp Alopecia Areata

The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between p...

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin ...

PubMed Articles [7616 Associated PubMed Articles listed on BioPortfolio]

Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.

Alopecia areata is an autoimmune disease involving the hair follicle with a chronic, relapsing course. Tofacitinib is Janus kinase inhibitor approved for treatment of rheumatoid arthritis that has bee...

Association of alopecia areata with hospitalization for mental health disorders in US adults.

Patients with alopecia areata have multiple risk factors for mental health disorders, including psychological distress and impaired quality of life. Alopecia areata was associated with increased menta...

Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.

Data on treatment options in pediatric alopecia areata are limited. Topical anthralin has been demonstrated to be an effective treatment option in adults and has minimal systemic toxicity. Prior resul...

Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata.

Androgenetic alopecia (AGA) and alopecia areata (AA) are common causes of alopecia which can sometimes be difficult to differentiate clinically. Horizontal sections of scalp biopsies are used to study...

The value of dermoscopy in diagnosing eyebrow loss in patients alopecia areata and frontal fibrosing alopecia.

Alopecia areata and frontal fibrosing alopecia are common causes of eyebrow loss (madarosis).

Medical and Biotech [MESH] Definitions

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type G. Though it has been isolated from soil, no outbreaks involving this type have been recognized.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type C which is neurotoxic to ANIMALS, especially CATTLE, but not humans. It causes dissociation of ACTIN FILAMENTS.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type D which is neurotoxic to ANIMALS, especially CATTLE, but not humans.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type F which is neurotoxic to humans and animals.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type E which is neurotoxic to humans and animals.

More From BioPortfolio on "The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial